Open AccessComparison of prognoses according to non‐positive and positive spectrin α II expression detected immunohistochemically in epithelial ovarian carcinoma: a retrospective study.
Author(s) -
Maeda Osamu,
MiyataTakata Tomoko,
Shibata Kiyosumi,
Kajiyama Hiroaki,
Mizuno Mika,
Tamakoshi Koji,
Shimoyama Yoshie,
Nakamura Shigeo,
Kikkawa Fumitaka
Publication year - 2016
Publication title -
cancer medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.403
H-Index - 53
ISSN - 2045-7634
DOI - 10.1002/cam4.683
Subject(s) - ovarian carcinoma , immunohistochemistry , hazard ratio , medicine , proportional hazards model , oncology , serous fluid , log rank test , pathology , confidence interval , ovarian cancer , cancer
Anticancer drug sensitivity affects prognosis in ovarian carcinoma. Previously, we purified spectrin α II and β II tetramers from cisplatin‐resistant ovarian serous adenocarcinoma cells and demonstrated that they contribute to platinum anticancer drug resistance. In this clinical study, we focused on the role of spectrin α II expression. It is our objective to demonstrate the potential of spectrin α II expression as a useful predictor of anticancer drug resistance and postoperative prognosis in epithelial ovarian carcinoma. Spectrin α II expression in the ovarian adenocarcinoma surgical specimens of 193 patients was examined by immunohistochemical staining. Staining strength was scored 3+, regarded as positive expression, and 2+, 1+, and 0, regarded as non‐positive expression. Prognoses obtained from clinical records were evaluated by statistical analysis. In the 193 cases studied, positive spectrin α II expression was associated with worse overall survival when compared with non‐positive expression ( P < 0.001 by log‐rank test), and spectrin α II expression was identified as an independent predictive factor of overall survival (hazard ratio[HR]: 3.77, 95% confidence interval[CI]: 1.77–8.00; P < 0.001 by multivariate Cox's proportional hazards model). In the study about progression‐free survival, spectrin α II expression was not associated with prognoses. However, similar results as overall survival were obtained for survival after recurrence of the 92 recurrent cases ( P = 0.0051 by log‐rank test, HR: 4.49, 95% CI: 2.06–9.79; P < 0.001 by multivariate Cox's proportional hazards model). In a detailed overall survival study of 66 serous adenocarcinoma patients and 127 nonserous adenocarcinoma patients, similar results were also obtained. Spectrin α II expression is a useful predictor of anticancer drug resistance and postoperative prognosis in epithelial ovarian carcinoma..